Trinity, a company providing insights and analytics services to drug developers, announced the acquisition of Bell Canyon Consulting, a developer of data management software.
Through the acquisition, Trinity aims to build on its existing Commercial Data Solutions Suite, and expand it to include early-stage development projects, according to David Fitzhenry, the company’s CEO.
The final data management software product to be developed is expected to facilitate and accelerate the decision making of drug developers, by providing a “tailored execution plan to map information needs,” as well as customizable reports and dashboards, the company stated.
Asked about the importance of data management in accelerating drug development, Fitzhenry told us that “Foundationally, good data is critical to inform key decisions being made across the organization, but often hard to effectively manage and govern.”
According to the CEO, enabling cross-functional teams within a drug development organization to access a ‘single version of the truth’ based on aligned metrics and key performance indicators will accelerate decision making.
“This results in greater lead time, as well as to the ability for enhanced planning,” he added.
Fitzhenry also told us that while improved data management is a key benefit of the integration, “the combined organization will also enhance business intelligence capabilities, including reporting and analytics.”
